FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239095818> ?p ?o ?g. }

• W4239095818 endingPage "381" @default.
• W4239095818 startingPage "381" @default.
• W4239095818 abstract "381 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during the transition from a localized to metastatic disease. Most patients initially respond to inhibitors of the AR pathway, but the response is often short-lived. The majority of patients progressing on enzalutamide or abiraterone exhibit genetic alterations in the AR locus, either in the form of amplifications or point mutations in the AR gene. Given these mechanisms of resistance, our goal is to eliminate the AR protein using the PROteolysis TArgeting Chimera (PROTAC) technology. Methods: Here we report an orally bioavailable small molecule AR PROTAC that leads to ubiquitination and degradation of AR. This molecule has been characterized in in vitro degradation and functional assays, DMPK, toxicology and preclinical efficacy studies. Results: This AR PROTAC completely degrades AR in all cell lines tested, with an observed 50% degradation concentration (DC 50 ) < 1 nM. PROTAC-mediated AR degradation suppresses the expression of the AR-target gene PSA, inhibits AR-dependent cell proliferation, and induces potent apoptosis in VCaP cells. The AR PROTAC degrades all clinically relevant mutant AR proteins and retains activity in a high androgen environment. In mouse xenograft studies, greater than 90% AR degradation is observed at a 1 mg/kg PO QD dose. Significant inhibition of tumor growth and AR signaling can be achieved in both an intact and castrate setting. Further, the AR PROTAC demonstrates in vivo efficacy and reduction of oncogenic Erg protein in a long term, castrate, enzalutamide-resistant VCaP tumor model. DMPK and exploratory toxicology studies show robust oral, dose proportional drug exposure in rodent and non-rodent species. Conclusions: In summary, we report preclinical data on an orally bioavailable AR PROTAC degrader that demonstrates efficacy in enzalutamide-resistant prostate cancer." @default.
• W4239095818 created "2022-05-12" @default.
• W4239095818 creator A5000114373 @default.
• W4239095818 creator A5000833342 @default.
• W4239095818 creator A5007363139 @default.
• W4239095818 creator A5007702221 @default.
• W4239095818 creator A5016866989 @default.
• W4239095818 creator A5024137095 @default.
• W4239095818 creator A5033072455 @default.
• W4239095818 creator A5034584033 @default.
• W4239095818 creator A5037677450 @default.
• W4239095818 creator A5038644541 @default.
• W4239095818 creator A5039592991 @default.
• W4239095818 creator A5050030250 @default.
• W4239095818 creator A5050229370 @default.
• W4239095818 creator A5055366079 @default.
• W4239095818 creator A5064251798 @default.
• W4239095818 creator A5065771969 @default.
• W4239095818 creator A5084210456 @default.
• W4239095818 creator A5084792895 @default.
• W4239095818 date "2018-02-20" @default.
• W4239095818 modified "2023-10-06" @default.
• W4239095818 title "An oral androgen receptor PROTAC degrader for prostate cancer." @default.
• W4239095818 doi "https://doi.org/10.1200/jco.2018.36.6_suppl.381" @default.
• W4239095818 hasPublicationYear "2018" @default.
• W4239095818 type Work @default.
• W4239095818 citedByCount "14" @default.
• W4239095818 countsByYear W42390958182019 @default.
• W4239095818 countsByYear W42390958182020 @default.
• W4239095818 countsByYear W42390958182021 @default.
• W4239095818 countsByYear W42390958182022 @default.
• W4239095818 countsByYear W42390958182023 @default.
• W4239095818 crossrefType "journal-article" @default.
• W4239095818 hasAuthorship W4239095818A5000114373 @default.
• W4239095818 hasAuthorship W4239095818A5000833342 @default.
• W4239095818 hasAuthorship W4239095818A5007363139 @default.
• W4239095818 hasAuthorship W4239095818A5007702221 @default.
• W4239095818 hasAuthorship W4239095818A5016866989 @default.
• W4239095818 hasAuthorship W4239095818A5024137095 @default.
• W4239095818 hasAuthorship W4239095818A5033072455 @default.
• W4239095818 hasAuthorship W4239095818A5034584033 @default.
• W4239095818 hasAuthorship W4239095818A5037677450 @default.
• W4239095818 hasAuthorship W4239095818A5038644541 @default.
• W4239095818 hasAuthorship W4239095818A5039592991 @default.
• W4239095818 hasAuthorship W4239095818A5050030250 @default.
• W4239095818 hasAuthorship W4239095818A5050229370 @default.
• W4239095818 hasAuthorship W4239095818A5055366079 @default.
• W4239095818 hasAuthorship W4239095818A5064251798 @default.
• W4239095818 hasAuthorship W4239095818A5065771969 @default.
• W4239095818 hasAuthorship W4239095818A5084210456 @default.
• W4239095818 hasAuthorship W4239095818A5084792895 @default.
• W4239095818 hasConcept C121608353 @default.
• W4239095818 hasConcept C126322002 @default.
• W4239095818 hasConcept C134018914 @default.
• W4239095818 hasConcept C207001950 @default.
• W4239095818 hasConcept C2776551883 @default.
• W4239095818 hasConcept C2777911890 @default.
• W4239095818 hasConcept C2779723316 @default.
• W4239095818 hasConcept C2780192828 @default.
• W4239095818 hasConcept C2992195973 @default.
• W4239095818 hasConcept C502942594 @default.
• W4239095818 hasConcept C54355233 @default.
• W4239095818 hasConcept C61367390 @default.
• W4239095818 hasConcept C71315377 @default.
• W4239095818 hasConcept C71924100 @default.
• W4239095818 hasConcept C86803240 @default.
• W4239095818 hasConcept C95444343 @default.
• W4239095818 hasConceptScore W4239095818C121608353 @default.
• W4239095818 hasConceptScore W4239095818C126322002 @default.
• W4239095818 hasConceptScore W4239095818C134018914 @default.
• W4239095818 hasConceptScore W4239095818C207001950 @default.
• W4239095818 hasConceptScore W4239095818C2776551883 @default.
• W4239095818 hasConceptScore W4239095818C2777911890 @default.
• W4239095818 hasConceptScore W4239095818C2779723316 @default.
• W4239095818 hasConceptScore W4239095818C2780192828 @default.
• W4239095818 hasConceptScore W4239095818C2992195973 @default.
• W4239095818 hasConceptScore W4239095818C502942594 @default.
• W4239095818 hasConceptScore W4239095818C54355233 @default.
• W4239095818 hasConceptScore W4239095818C61367390 @default.
• W4239095818 hasConceptScore W4239095818C71315377 @default.
• W4239095818 hasConceptScore W4239095818C71924100 @default.
• W4239095818 hasConceptScore W4239095818C86803240 @default.
• W4239095818 hasConceptScore W4239095818C95444343 @default.
• W4239095818 hasIssue "6_suppl" @default.
• W4239095818 hasLocation W42390958181 @default.
• W4239095818 hasOpenAccess W4239095818 @default.
• W4239095818 hasPrimaryLocation W42390958181 @default.
• W4239095818 hasRelatedWork W1528618484 @default.
• W4239095818 hasRelatedWork W2104364640 @default.
• W4239095818 hasRelatedWork W2740124347 @default.
• W4239095818 hasRelatedWork W2772229485 @default.
• W4239095818 hasRelatedWork W2806156214 @default.
• W4239095818 hasRelatedWork W2948523439 @default.
• W4239095818 hasRelatedWork W3112701574 @default.
• W4239095818 hasRelatedWork W3181847396 @default.
• W4239095818 hasRelatedWork W3198382015 @default.
• W4239095818 hasRelatedWork W4380146458 @default.
• W4239095818 hasVolume "36" @default.

• next